On November 13th, the Associated Press released an article showing mixed reviews of Arcoxia, the cox-2 inhibitor drug that Merck is hoping to market as a replacement for its drug Vioxx. Merck pulled Vioxx off the market in late 2004 because of studies showing an increased risk of heart attack / cardiovascular events when taking the drug.
The results of 3 studies were due to be published this week in the British journal called the Lancet and also presented at an American Heart Association...
Can I Take Arcoxia With Painkiller?
Featured Health Expert
More information on "Can I Take Arcoxia With Painkiller?"
From Our Experts
EXPERT
FDA Rejects Merck's Arcoxia Drug
By Christine Miller, Health Expert
In a widely expected decision, the FDA has sent Merck a "non-approvable letter" for Arcoxia. The letter said before Arcoxia has another... Read more »
EXPERT
FDA Advisory Panel to Evaluate Arcoxia, a Vioxx Replacement
By Christine Miller, Health Expert
On Thursday, April 12 an FDA advisory panel will discuss whether or not to recommend that the FDA approve Merck & Co’s... Read more »
EXPERT
FDA Rejects Osteoarthritis Drug Arcoxia
By Christine Miller, Health Expert
On April 12th, a Food and Drug Administration, FDA, advisory panel of experts rejected Merck’s drug, Arcoxia, in a 20-1 vote. It is a... Read more »
EXPERT
Painkillers Can be More Effective Than Antipsychotics in Treating...
By Christine Kennard, Health Expert
Agitation causes untold misery for people with dementia, and their caregivers. A new study by researchers from the England and Norway has... Read more »
From Our Sources
FDA advisory panel rejects new COX-2 painkiller
A panel of experts that advises the U.S. Food and Drug Administration (FDA) has recommended that the new COX-2 inhibitor Arcoxia should not be... Read more »
Data on new COX-2 painkiller set to be released
Results from a large study on Merck's new COX-2 inhibitor drug, Arcoxia, are about to be released. Many doctors and patients are awaiting the results... Read more »
Arcoxia safety study gives mixed results
An advisory panel to the U.S. Food and Drug Administration has found mixed results about the safety of the new COX-2 inhibitor Arcoxia. In a recent... Read more »
Clinical trial: Arcoxia and rheumatoid arthritis
This is a study to assess different doses of Arcoxia/MK-0663 in the treatment of patients with rheumatoid arthritis. This national study is currently... Read more »
Data on COX-2 inhibitor Arcoxia gives good--and bad--news
A new study on the COX-2 inhibitor Arcoxia is intensifying worries about the drug's safety. Though researchers found that the new drug had similar... Read more »
Featuring Content From:
By using this service, you accept our Terms of Use. Please read them. The consumer health information on is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2012 Remedy Health Media, LLC. All Rights Reserved.
